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Summary
This paper aimed to review the current status of UGT1A1 polymorphisms as a pharmacogenetic marker for prediction 
of irinotecan-induced toxicities in metastatic colorectal cancer. Deficiencies in the activity uridine diphosphate glucuro-
nosyltransferases (UGT) are mostly due to gene polymorphisms and can lead to increased exposure to irinotecan and its 
active metabolite causing severe, sometimes life-threatening treatment-related toxicities. Although data suggest that UGT1A1 
polymorphisms, especially homozygous (UGT1A1*28/*28, UGT1A1*6/*6) are related to severe irinotecan toxicity and some 
guidelines highlighted the importance of upfront UGT1A1 genotyping in order to give safer irinotecan dose, UGT1A1 geno-
typing is currently not being routinely performed in the daily clinical practice. It is important to note that genetic polymor-
phisms of UGT1A1 show ethnic differences and it is suggested that Caucasian patients should be upfront screened for 
UGT1A1*28 and Asian patients for UGT1A1*6 as these polymorphisms are common genetic variation in these populations. 
Data regarding the association of UGT1A1 polymorphisms and treatment response and survival are conflicting.
Nevertheless, it is important to think about other genetic variations in the context of chemotherapy-induced toxicities, 
especially dihydropyrimidine dehydrogenase deficiency (DYPD).
In conclusion, UGT1A1 polymorphisms are pharmacogenetic markers which can be used for stratification of patients 
who are at higher risk of irinotecan-induced toxicities to allow preventive dose reduction to reduce potential toxicities.
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UGT1A1 POLIMORFIZMI KAO PREDIKTIVNI FARMAKOGENETIČKI BILJEZI IRINOTEKANSKE TOKSIČNOSTI  
U BOLESNIKA S METASTATSKIM KOLOREKTALNIM KARCINOMOM
Sažetak
Cilj ovog rada je bio napraviti pregled trenutnog statusa UGT1A1 polimorfizama kao farmakogene tičkih biljega za 
predviđanje toksičnosti na irinotekansku kemoterapiju u bolesnika s metastatskim kolorektalnim karcinomom. Nedostatci 
u aktivnosti uridin-difosfat–glukuronoziltransferaze (UGT) su uglavnom zbog polimorfizama gena i mogu dovesti do 
 povećane izloženosti irinotekanu i njihovom aktivnom metabolitu uzrokujući ozbiljne, ponekad životno ugrožavajuće nus-
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pojave. Iako podatci sugeriraju da su UGT1A1 polimorfizmi, posebice homozigoti (UGT1A1*28/*28, UGT1A1*6/*6), povezani 
s ozbiljnim irinotekanskim nuspojavama i neke smjernice ističu značaj genotipizacije UGT1A1 prije početka liječenja irinoteka-
nom u svrhu davanja sigurnije doze irinotekana, UGT1A1 genotipizacija se trenutno rutinski ne provodi u kliničkoj praksi.
Važno je naglasiti da UGT1A1 genski polimorfizmi pokazuju etničke razlike te se preporuča da se bijelci testiraju na 
UGT1A1*28, a azijati na UGT1A1*6 s obzirom da su ti polimorfizmi najčeće genske varijacije u tim populacijama. Podatci o po-
vezanosti UGT1A1 polimorfizama i odgovora na terapiju i preživljenje su proturječni. Također je bitno misliti i na druge genet-
ske varijacije u kontekstu kemoterapijom-inducirane toksičnosti, posebice nedostatka enzima dihidropirimidin dehidrogenaze.
U zaključku, UGT1A1 polimorfizmi su farmakogenetički biljezi koji bi se mogli koristiti za izdvajanje pacijenata koji 
su pod većim rizikom za razvijanje irinotekanom-inducirane toksičnosti i omogućiti im preventivno smanjenje doze u svrhu 
smanjenja potencijalne toksičnosti.
KLJUČNE RIJEČI:  uridin-difosfat– glukuronoziltransferaza, genski polimorfizmi, kolorektalni karcinom,  
irinotekanom izazvane nuspojave
INTRODUCTION
Colorectal cancer (CRC) is the third most com-
mon cancer in men (746,000 cases, 10.0% of the to-
tal) and the second in women (614,000 cases, 9.2% 
of the total) worldwide (1). The overall survival of 
patients with metastatic CRC has increased to ap-
proximately 3 years with current therapy (2). Treat-
ment options for CRC are dependent on the stage 
of the disease, tumor biology, patients general con-
dition, comorbidities, previous therapy and their 
wishes. Chemotherapy-induced toxicities are very 
important factor because they can restrict the clini-
cal application of chemotherapy.
Irinotecan is a topoisomerase 1 inhibitor, it 
binds to the DNA/topoisomerase I complex dur-
ing DNA replication, preventing the resealing of 
single-strand breaks. Irinotecan is a cornerstone 
chemotherapy agent for the first-line treatment of 
metastatic colorectal cancer (mCRC) together with 
5-fluorouracil (5-FU) and oxaliplatin with the ad-
dition of targeted therapy according to NRAS/
KRAS/BRAF status; epidermal growth factor re-
ceptors (EGFR) inhibitors cetuximab/panitumum-
ab or anti-vascular endothelial growth factor 
(VEGF) bevacizumab (2,3).
Irinotecan is usually co-administered with in-
fusional 5-fluorouracil/leucovorin (FOLFIRI regi-
men), with the addition of targeted therapies, as a 
front line for patients with metastatic colorectal 
cancer. Irinotecan treatment has an acceptable safe-
ty profile in most patients, but up to 35% of patients 
treated with combination regimens of 5-FU and iri-
notecan experience clinically relevant treatment-
related toxicities, mainly diarrhea, stomatitis and 
myelosuppression (4,5). The number of clinically 
relevant treatment-related toxicities increases sig-
nificantly, up to 35-50%, with the intensification of 
the treatment using triplet regimen (FOLFOXIRI; 
5-FU, oxaliplatin and irinotecan) (6,7).
Irinotecan is converted into its active form 
7-ethyl-10-hydroxycamptothecin (SN-38) by a 
 carboxylsterase and inactivated through uridine 
diphosphate glucuronosyltransferase (UGT1A1). 
Several isoforms of UDP-glucuronosyltransferase 
(UGT) enzyme are responsible for hepatic biliru-
bin glucuronidation (8). The glucuronidation of 
an active form of irinotecan (SN-38) is catalyzed 
by UGT1A1, UGT1A3, UGT1A6 and UGT1A9, but 
UGT1A1 has the highest activity. Thus, reduced 
UGT1A1 expression can affect on irinotecan me-
tabolism and lead to increased risk of irinotecan 
associated toxicity (8).
Genetic variations within the UGT1A1 gene, 
known as polymorphisms, can lead to decreased 
enzyme activity and are associated with a higher 
risk of severe toxicity with irinotecan, such as neu-
tropenia and diarrhea. UGT1A1*1 is a common 
variation with six TA repeats in promoter region 
while the seven-repeat variant UGT1A1*28is re-
sponsible for a dramatically reduced expression of 
UGT1A1 causing an increase in adverse events due 
to poor metabolism of the SN38 active metabolite of 
irinotecan (9,10). UGT1A1*28 homozygote geno-
type was found in less than 10% of the Croatian 
population (11). UGT1A1*6, a nonsynonymous 
single nucleotide polymorphism (SNP) in exon 1, 
was frequently found in an Asian population (12).
Clinical significance  
of UGT1A1 gene polymorphisms
Clinically relevant, dose-limiting irinotecan-
related toxicities include myelosuppression diar-
rhea and dehydration (13). Several meta-analy- 
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ses were conducted to asses the association of 
UGT1A1 gene polymorphisms and the occurrence 
of irinotecan-related severe neutropenia and diar-
rhea. Majority of them included other tumor sites 
beside CRC (14-19). Other limitations were the in-
clusion of patients who were treated with differ-
ent chemotherapy protocols, different doses of 
irinotecan, different polymorphism detection 
methods were used across studies (14-20). The 
most relevant meta-analysis from Liu et al. assess-
ing the association of UGT1A1 gene polymor-
phisms and irinotecan-induced neutropenia and 
diarrhea included only patients with CRC. It 
showed more than fourfold (OR 4.79, 95% CI 3.28-
7.01; P<0.00001) increase in the risk of neutropenia 
for UGT1A1*1/*28 genotype, and twofold (OR 
1.90, 95% CI: 1.44-2.51; P<0.00001) increase in the 
risk of neutropenia for UGT1A1*1/*28 genotype, 
compared to UGT1A1*1/*1. The risk of diarrhea 
was around twofold increased (OR 1.84, 95% CI 
1.24–2.72; P<0.002) for UGT1A1*28 homozygous 
patients compared to UGT1A1*1/*1 (20).
Conflicting data were published regarding 
the association of UGT1A1*28 polymorphisms 
and response to chemotherapy and survival out-
comes (21-26). Recent Liu et al meta-analysis 
showed that UGT1A1*28 polymorphisms were as-
sociated with a higher response among patients 
with metastatic colorectal cancer (OR 1.24, 95%CI 
1.05–1.48) compared to UGT1A1*1/*1 (19).
A dose of irinotecan seems to be relevant for 
irinotecan-related toxicities. Metaanalysis from 
Hu et al. showed no association between UG-
T1A1*28 genotype and severe diarrhea treated 
with low doses of irinotecan (<125 mg/m2) (RR 
0.65, 95% CI 0.27-1.58), while the risk of severe di-
arrhea was significantly higher for patients with 
UGT1A1*28 genotype treated with medium or 
high irinotecan doses (OR 1.79, 95% CI 1.08–2.97 
– medium dose, OR 2.32 95% CI 1.25-4.28 – high 
dose) (15). In subgroup meta-analysis of Liu et al. 
also showed higher incidence of diarrhoea in UG-
T1A1*28/*28 patients treated with higher dose of 
irinotecan (>150 mg/m2) (OR=2.37, 95% CI: 1.39-
4.04; P=0.002) while patients with UGT1A1*1/*28 
genotype had slightly increased risk (OR 1.39, 
95% CI: 0.97–1.98; P 1⁄4 0.07) of borderline signifi-
cance (20).
Hoskins et al suggested that association be-
tween UGT1A1*28 genotype and neutropenia is 
dose-dependent and that it had no effect on pa-
tients treated with low dose of irinotecan (<150 
mg/m2) while on the other hand, Hu et al found 
that UGT1A1*28/28* genotype was associated 
with an increased risk of neutropenia even at low 
doses (RR 2.43 – low dose <150mg/m2, RR 2.00 
medium-dose 150-250 mg/m2, RR 7.22 high dose 
>250mg/m2) (16, 18).
In a trial designed to define the maximum 
tolerated dose according to UGT1A1 genotype 
maximum tolerable dose in patients with UGT1A1 
*28/*28 genotype was found to be 30% lower than 
the standard dose of 180 mg/m2 (27).
There are concerns that reduced dose will not 
be equally effective, and an open question wheth-
er patients with UGT1A1 *28/*28 genotype should 
be treated with other chemotherapeutic regimens 
which would be more suitable and effective for 
them (5).
A recent study from Fujii et al. showed that 
incidence rates of hematological as well as non-
hematological toxicities were not significantly dif-
ferent among patients with different UGT1A1 
polymorphisms when the initial dose of irinote-
can was reduced by 20% in patients with homozy-
gous mutations. The study also showed that the 
reduction in the initial dose of irinotecan by 20% 
in mCRC patients with homozygous mutations in 
UGT1A1 genes did not impair efficacy of chemo-
therapy containing irinotecan (28).
Current status of UGT1A1 gene  
polymorphism screening
Genetic polymorphisms of UGT1A1 show 
ethnic differences. It is reported that UGT1A1*28 
occurs with a frequency of 0.26–0.31 in Cauca-
sians, 0.42–0.56 in African Americans, and 0.09–
0.16 in Asian populations, while UGT1A1*6 has 
allele frequencies of around 0,2 for Asian popula-
tion (29-31).
Several meta-analyses in Asian-only patients 
showed a lesser association between UGT1A1*28 
compared to UGT1A1*6 genotype and irinotecan-
induced neutropenia, suggesting that UGT1A1*6 
genotype could be a good predictor of irinotecan-
induced toxicity in this population (16,17). It is 
recommended that Caucasian patients should be 
upfront screened for UGT1A1*28 and Asian pa-
tients for UGT1A1*6 as these polymorphisms are 
common genetic variation in these populations 
(32). Both of these polymorphisms can result in 
approximately 70% reduction of UGT1A1 activity 
in carriers causing increased systemic exposure to 
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irinotecan and SN-38 in homozygous patients for 
these variants and increase the risk of irinotecan-
related toxicities (32).
Current FDA recommendation regarding 
dose reduction in patients homozygous for the 
UGT1A1*28 allele receiving irinotecan is not pre-
cise. The Dutch Pharmacogenetics Working Group 
(DPWG) of the Royal Dutch Association for the 
Advancement of Pharmacy (KNMP) recommends 
starting with 30% reduced dose for homozygous 
carriers of the UGT1A1*28 allele with the possibil-
ity to increase the dose if well tolerated, guided by 
the neutrophil count. Also stating that no action is 
needed for heterozygous carriers of the UG-
T1A1*28 allele. French National Network of Phar-
macogenetics (RNPGx) has dose-dependent rec-
ommendation stating that presence of the UG-
T1A1*28 allele is not a major risk factor for patients 
treated with lower doses of irinotecan (<180 mg/
m2), at medium doses (180—230 mg/m2) 25-30% 
dose reduction is recommended for patients ho-
mozygous for the UGT1A1*28 allele, while the ad-
ministration of irinotecan at this higher dose (>230 
mg/m2) is contraindicated for homozygous for the 
UGT1A1*28 allele and leading to discussion of a 
standard dose depending on the associated risk 
factors. High dose of irinotecan (240 mg/m2) is 
recommended only for *1/*1 patients, or for het-
erozygous UGT1A1*28 patients who have no oth-
er risk factors and who benefit from intensive sur-
veillance (33-36).
Current NCCN guidelines state that although 
commercial tests are available to detect the UG-
T1A1*28 allele guidelines for use of this test in clin-
ical practice have not been established. Further-
more, UGT1A1 testing on patients who experi-
enced irinotecan toxicity is not recommended, as 
they will require a dose reduction regardless of the 
UGT1A1 test result (3). Therefore, the adoption of 
an upfront UGT1A1*28 genotyping to increase iri-
notecan safety in clinical practice is still limited and 
currently not routinely performed (32).
The patient safety and clinical outcomes 
could be substantially improved by upfront UG-
T1A1 screening and UGT1A1- guided dose indi-
vidualization to predict, diminish and even avoid 
toxicity to improve the therapeutic effect of irino-
tecan (5).
The recent cost-effective analysis showed 
that the costs of the management of irinotecan-re-
lated toxicity are significantly higher in patients 
carrying either a *28/*28 or a *1/*28, as compared 
to *1/*1 genotype. The cost of all toxicities man-
agement per patient increased 1.4 folds for *1/*28 
carriers in comparison to *1/*1, and 6-fold for the 
*28/*28 patients (37).
Other pharmacogenetic markers  
for CRC chemotherapy-related toxicity
Irinotecan has a toxicity profile which over-
laps with those of fluoropyrimidines (5-fluoroura-
cil and capecitabine). Dihydropyrimidine dehy-
drogenase (DYPD) gene encodes for the enzyme 
dihydropyrimidine dehydrogenase (DPD), which 
is important for the metabolism of fluoropyrimi-
dines and de-activates more than 80% of adminis-
tered fluoropyrimidine. Factors such as age, race, 
comorbidities, and concomitant therapies also in-
fluence metabolism (38).
Reduced or absent activity of this enzyme in 
DYPD deficient patients can result in severe and 
sometimes fatal toxicity; severe and prolonged 
pancytopenia, sometimes associated with sepsis, 
serious gastrointestinal toxicity with refractory di-
arrhea and dehydration, severe mucositis and se-
vere skin changes (39-41). There are numerous 
genetic variants in DPYD, but four DPYD variants 
causing decreased function were shown to be 
 important for patients treated with fluoropyri-
midines: c.1905+1G>A (rs3918290, also known 
as DPYD*2A, DPYD:IVS14 + 1G>A), c.1679T>G 
(rs55886062, DPYD *13, p.I560S), c.2846A>T 
(rs67376798, p.D949V), and c.1129–5923C>G 
(rs75017182, HapB3). Among those c. 1905+1G>A 
and c.1679T>G have the most deleterious impact 
on DPD activity (40).
Around ~7% of Europeans carry at least one 
decreased function DPYD variant. The most com-
mon is c.1129–5923C>G decreased function DPYD 
variant with carrier frequencies of 4.1–4.8%, while 
carrier frequency for c.1905+1G>A is much rarer, 
1–1.2% (40).
Currently upfront DPYD genotyping re-
mains controversial, as it is the case with UGT1A1 
genotyping.
Furthermore, other genetic variation includ-
ing the carboxylesterase 1 (CES1) gene, the multi-
drug resistance-associated protein 2 (MRP2) gene, 
and organic anion-transporter family, member 
1B1 (OATP1B1; SLCO1B1) gene, are suggested to 
be associated with interindividual variability in 
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the pharmacokinetics and subsequently with tox-
icity to irinotecan (12).
CONCLUSION
Irinotecan is a crucial component of chemo-
therapy regimens for the treatment of metastatic 
colorectal cancer. UGT1A1 polymorphisms can 
cause a reduction in enzymatic activity that can in-
duce severe, sometimes life-threatening toxicities 
with a standard dose of irinotecan. Therefore, us-
ing UGT1A1 polymorphisms would be beneficial 
with the rationale to personalize the dosing of iri-
notecan according to UGT1A1 genotype status to 
reduce toxicities and optimize treatment effect, al-
though its use as an upfront screening to increase 
irinotecan safety is still limited and currently not 
routinely performed in the daily clinical practice.
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